



Published in final edited form as:

J Immunol. 2017 January 15; 198(2): 623–628. doi:10.4049/jimmunol.1601686.

Adenosine A2a receptor signals inhibit germinal center T follicular helper cell differentiation during the primary response to vaccination

Shirdi E. Schmiel^{*}, Jessica A. Yang[†], Marc K. Jenkins[†], and Daniel L. Mueller^{*}

^{*}Departments of Medicine, Center for Immunology, University of Minnesota Medical School, Minneapolis, MN 55455, USA

[†]Departments of Microbiology and Immunology, Center for Immunology, University of Minnesota Medical School, Minneapolis, MN 55455, USA

Abstract

Adenosine A2a receptor (A2aR) signaling acts as a barrier to autoimmunity by promoting anergy, inducing regulatory T cells (Tregs), and inhibiting effector T cells. However, *in vivo* effects of A2aR signaling on polyclonal CD4 T cells during a primary response to foreign antigen has yet to be determined. To address this problem, we immunized mice with peptide antigen 2W1S coupled to PE in CFA and treated with the selective A2aR agonist CGS-21680 (CGS). 2W1S:I-A^b-specific tetramer-binding CD4 T cells did not become anergic or differentiate into Foxp3⁺ Tregs. Additionally, CGS treatment did not inhibit Th1 or Th17 differentiation. However, CGS did abrogate germinal center (GC) T follicular helper (Tfh) cells, and blunted PE-specific GC B cell responses. The use of A2aR-deficient CD4 T cells established that this CGS effect was T cell-intrinsic. Therefore, this study has identified a unique role for A2aRs in regulating CD4 T cell differentiation during vaccination.

Introduction

Adenosine is a purine nucleoside that regulates a broad spectrum of physiological responses via four different G coupled-protein receptors (A1, A2a, A2b, and A3). Adenosine A2a receptors (A2aRs) are expressed primarily on cells of hematopoietic origin, particularly on activated cytotoxic CD8 and helper CD4 T cells (1,2,3). Studies using mouse models of T cell-mediated autoimmune disorders (4,5) as well as graft-versus-host disease (6) have shown that A2aR signaling can restore immune homeostasis by promoting the induction of T cell anergy and regulatory T cell (Treg) differentiation. Loss of A2aR signaling in *Adora2a*-deficient mice also leads to enhanced control of tumor growth by CD8 T cells (7). *In vitro* polarizing assays suggest that A2aR signaling alters CD4 T cell differentiation by inhibiting the induction of Th1 (Tbet⁺), Th2 (GATA3⁺), and Th17 (RORγt⁺) effector T cell phenotypes (8,9). *In vivo* models of asthma (10), autoimmunity (4,5), and infection (11) also

Correspondence Address: Daniel L. Mueller, MD, University of Minnesota Medical School, Director of Rheumatic and Autoimmune Diseases, Dept. of Medicine, Campus Code: 2641, 3-186 Wallin Medical Biosciences Building, 2101 6th St. SE, Minneapolis, MN 55455, muell002@umn.edu.

suggest that A2aR signaling can reduce Th1 and Th17 responses. However, CD4 T cell differentiation during a primary response to foreign antigen in the context of vaccination has not been assessed.

Most investigations of A2aRs to date have correlated changes in disease outcome *in vivo* with the *in vitro* modulation of signaling in cloned T cells, TCR-transgenic T cells, or bulk primary T cells. None the less, Zarek *et al.* (4) took advantage of hemagglutinin and pigeon cytochrome c peptide-specific TCR-transgenic CD4 T cells made deficient for A2aRs (*Adora2a*^{-/-}) to show *in vivo* that both endogenous adenosine as well as an A2aR agonist can act to inhibit dangerous effector responses to an experimental self antigen and promote the development of anergy and Tregs. More recently, Shehade *et al.* (11) found that activation of A2aRs during acute infection with *Toxoplasma gondii* reduced the number of endogenous bulk IFN- γ producing CD4 T cells from secondary lymphoid organs. In cancer, an investigation of tumor antigen-specific CD8 polyclonal T cells in *Adora2a*-deficient mice has also indicated that endogenous adenosine limits their clonal expansion in response to tumor antigen (7). However, A2aR-mediated regulation of endogenous polyclonal antigen-specific CD4 T cells remains unknown.

To investigate the *in vivo* effects of A2aR signaling on naïve polyclonal CD4 T cells during a primary response to foreign antigen we utilized a vaccination approach that allowed us to track antigen-specific CD4 T cells that differentiate into various T cell lineages such as Th1, Th17, Tregs, and follicular helper T cells (Tfh). No reports to date have indicated a role for A2aR signaling in Tfh differentiation despite the role of other purinergic receptors such as P2X7 in regulating Tfh homeostasis (12). It is possible that A2aR mediated effects on Tfh cells may have been overlooked due a requirement of antigen specificity between T cells and B cells during Tfh differentiation (13). To address this we utilized a vaccine that consists of 2W1S peptide covalently coupled to phycoerythrin (PE) (14). This allowed us to look at the interplay between endogenous antigen specific 2W1S:I-A^b-specific T cells and PE-specific B cells (14). We initially sought to characterize polyclonal antigen-specific CD4 T cell anergy induction and Treg generation during A2aR signaling by tracking of 2W1S:I-A^b tetramer-binding T cells in mice treated with the selective A2aR agonist CGS-21680 (CGS). We discovered that CGS has no impact on the antigen-induced clonal expansion of polyclonal 2W1S-specific CD4 T cells, nor does it promote the induction of anergy or Treg differentiation in our vaccination system. CGS did not appear to reduce Th1 or Th17 differentiation; instead, A2aR signaling directly inhibited 2W1S:I-A^b-driven CD4 T cell differentiation toward the germinal center (GC)-Tfh fate, and reduced cognate GC B cell responses. Therefore, this work identifies a novel A2aR-mediated control mechanism during vaccination that regulates CD4 T differentiation and function.

Materials and Methods

Mice

B6 (WT) mice were purchased from Charles River Breeding Laboratories under a contract from the National Cancer Institute (Frederick, MD). *Adora2a*^{loxP} mice containing *loxP* sites on either side of exon 2 of the *Adora2a* gene (a gift from Joel Linden, La Jolla Institute for Allergy and Immunology, La Jolla, CA) (3) were crossed with CD4-Cre mice (a gift from

Michael Farrar, University of Minnesota, Minneapolis, MN) to generate conditional A2aR T cell knockout (KO) mice. Non-Cre littermates were used as WT controls. Mice were bred and housed in specific-pathogen free conditions in animal facilities at the University of Minnesota, Twin Cities. All experimental protocols were performed in accordance with guidelines of the University of Minnesota Institutional Animal Care and Use Committee and the National Institutes of Health.

Immunization and selective A2aR agonist treatment

Mice were given an intraperitoneal (i.p.) vaccine containing 200 μ l of 0.6 μ g of 2W1S peptide conjugated to 25 μ g of PE emulsified in Complete Freund's Adjuvant (CFA) (Sigma-Aldrich) as previously described (14). Mice were then given a 7d course of twice daily i.p. injection with the selective A2aR agonist, CGS-21680 (CGS; Tocris) 2.5 mg/kg or with vehicle alone (PBS) as previously described (4).

Cell enrichment and flow cytometry

Lymph nodes (LN) and spleens were collected and divided for separate enrichments of 2W1S:I-A^b tetramer-specific CD4 T cells and PE-specific B cells. 2W1S:I-A^b APC-labeled tetramers were used to stain and enrich for 2W1S-specific CD4 T cells (14). PE B cell enrichment was performed by mixing cell suspensions with 1 μ g of PE (ProZyme) (14). Isolation of PE-specific B cells and for 2W1S:I-A^b-specific CD4 T cells was done using magnetic beads (STEM cell Technologies) (14). Enriched 2W1S T cells were first surface stained with CXCR5 (2G8), PD-1 (J43), CD4 (RM4-5), CD44 (IM7), as well as with the irrelevant cell exclusion antibodies CD11c (N418), B220 (RA3-6B2), CD8 (53-6.7), and F4/80 (BM8), and then fixed/permeabilized using a fixation/permeabilization kit (eBioscience) followed by intracellular staining with Foxp3 (FJK-16s), Tbet (4B10), Bcl6 (K112-91), ROR γ t (Q31-378), and Ki67 (SoA15). Enriched PE-specific B cells were surface stained with B220 (RA3-6B2), GL7 (GL-7), CD38 (90), IgM (RMM-1), and IgD (11-26c.2a), as well as with the irrelevant cell exclusion antibodies CD11c (N418), CD4 (GK1.5), CD8 (53-6.7), and F4/80 (BM8), and then they were fixed/permeabilized using a fixation/permeabilization kit (eBioscience) and intracellular stained with goat anti-mouse Ig (H+L) (A11068). Anergy in 2W1S:I-A^b-specific CD4 T cells was assessed by staining with CD73 (TY11.8) and folate receptor 4 (FR4, 12A5) as previously outlined (15, 16). Cells were analyzed on a Fortessa (Becton Dickinson) flow cytometer and analyzed using FlowJo (TreeStar).

Statistical analysis

Statistical tests were performed using Prism (GraphPad) software, and p values were obtained using an unpaired one-tailed Student's t-test with a 95% confidence interval.

Results

Activation of adenosine A2a receptors during the primary response to vaccination fails to induce anergy or promote the differentiation of Foxp3⁺ Tregs

The activation of A2aRs in many biological systems is associated with the production of intracellular cAMP, a second-messenger known for its anti-proliferative function (17). To

investigate the effects of A2aR signaling during the primary CD4 T cell response to antigen, we used a tetramer of the major histocompatibility complex II I-A^b molecule containing the 2W1S peptide to study the *in vivo* proliferation and differentiation of polyclonal 2W1S:I-A^b-specific CD4 T cells following immunization with a 2W1S peptide coupled to PE in CFA. This vaccination approach induces 2W1S:I-A^b-specific CD4 T cells to undergo clonal expansion and differentiation to Th1, Th17, Tregs, and Tfh lineages (14). Coupling 2W1S and PE together also allows for the interplay between 2W1S-specific GC-Tfh cells and PE-reactive GC B cell. This occurs when PE-specific B cells internalize 2W1S-PE through BCR recognition of PE resulting in the display of 2W1S:I-A^b complexes, and allows them to exchange helper signals with 2W1S:I-A^b-specific CD4 T cells (14). The effects of A2aR activation were tested by treating immunized mice twice daily with the selective A2aR agonist CGS (2.5 mg/kgi.p.) or vehicle alone as a control (PBS) (4). As shown in figure 1A, the clonal expansion of the 2W1S:I-A^b-specific polyclonal CD4 T cell population as a whole was no different in CGS- or PBS-treated mice. Consistent with preserved clonal expansion, we also observed no increase in the number of 2W1S:I-A^b-specific Foxp3⁺ Tregs during this immunization in the presence of CGS (Fig. 1B). Therefore, A2aR signaling did not inhibit clonal expansion nor did it enhance Treg cell differentiation after vaccination with antigen in CFA.

We next examined the capacity of A2aR signaling to promote anergy in 2W1S:I-A^b-specific polyclonal CD4 T cells during vaccination. To test the effects of A2aR signaling on the development of anergy, we examined two surface molecules whose high gene expression marks functionally unresponsive anergic T cells: CD73 (*Nt5e*) and FR4 (*Izumo1r*) (15, 16). Remarkably, CGS treatment led to a reduction rather than rise in the number of 2W1S-specific CD4 T cells that expressed high levels of these two anergy markers (Fig. 1C). Also consistent with an inability to promote tolerance in this system, CGS treatment led to an increase in the fraction of 2W1S:I-A^b-specific CD4 T cells that continued to express high levels of the proliferative marker Ki67 at day 7 (Fig. 1D). Taken together, these data indicated that A2aR signaling cannot inhibit the proliferation of polyclonal antigen-specific CD4 T cells during antigen priming in the presence of a strong adjuvant, and does not promote Treg generation or anergy induction.

Activation of adenosine A2a receptors interferes with the differentiation of Tfh and GC-Tfh cells during antigen priming

Paradoxically, primed CD4 T cells in CGS-treated mice expressed even lower levels of the anergy markers CD73 and FR4 than mice exposed to vehicle alone (Fig. 1C). Previous studies have demonstrated moderate levels of FR4 and CD73 expressed on Tfh cells (18). Although the role of these two molecules in Tfh generation and function remains unknown, this observation led us to the hypothesis that A2aR signaling interferes with Tfh differentiation. Mice primed with 2W1S in CFA did develop a large population of CXCR5⁺ 2W1S:I-A^b-specific CD4 T cells that expressed moderate levels of FR4 and CD73 (Fig. 2A,B). In contrast, treatment of primed mice with CGS led to a loss in the generation of this FR4^{int} CD73^{int} CXCR5⁺ 2W1S:I-A^b-specific CD4 T cell subset.

To more formally assess A2aR-regulated Tfh differentiation, we investigated the expression of the cell surface marker PD-1 and the transcription factor Bcl6 in primed 2W1S:I-A^b-specific CD4 T cells (19,20). CD4T cells that express the highest levels of CXCR5, Bcl6, and PD-1 have been characterized as GC-Tfh cells (Bcl6^{hi} CXCR5^{hi}) and are known to provide cognate help to antigen-specific B cells within germinal centers, whereas CD4 T cells expressing lower levels are characterized as Tfh cells (Bcl6^{lo} CXCR5^{lo}) and reside at the T cell/B cell border (21). During primary immunization, CGS treatment reduced both the frequency and number of 2W1S:I-A^b-specific Tfh and GC-Tfh cells (Fig. 2C-E). Consistent with a shift toward alternate differentiation fates, CGS treatment also elicited a small but significant increase in the number of 2W1S:I-A^b-specific non-Tfh cells. Therefore, our experiments revealed a novel role for A2aR pathway activation in the inhibition of Tfh and GC-Tfh cell differentiation.

A2aR inhibition of Tfh differentiation is T cell intrinsic

Although A2aR expression is known to be highly induced on CD4 T cells following TCR ligation (1-3), the expression of this adenosine receptor might also be expected on other cells of hematopoietic origin. Additionally, Tfh cell differentiation is a multifactorial process whose regulation likely involves multiple additional cell types, particularly dendritic cells and B cells (19-21). Therefore, it was important to determine whether the effects of CGS were the result of direct A2aR engagement on the 2W1S:I-A^b-specific CD4 T cells. To address this question, CD4-Cre *Adora2a*^{fl/fl} conditional knock-out (KO) mice lacking A2aRs only on their T cells were immunized with 2W1S-PE and compared to wild type (WT) A2aR-expressing littermates following a 7d course of CGS treatment. In the absence of T cell-expressed A2a receptors, CGS treatment lost its capacity to reduce Bcl6 expression and block 2W1S:I-A^b-specific GC-Tfh differentiation, and its inhibitory effects on Tfh cells appeared greatly blunted (Fig. 3A,B). Likewise, treatment of CD4-Cre *Adora2a*^{fl/fl} mice with CGS failed to induce an increase in non-Tfh cells during 2W1S antigen priming. Given that Bcl6 promotes differentiation to the Tfh and GC-Tfh fates in part by repressing other lineage-specific transcription factors such as Tbet and ROR γ t (19, 20), we further assessed these non-Tfh cells. WT mice significantly increased the frequency and number of 2W1S:I-A^b-specific ROR γ t⁺ Th17 cells when their A2aRs were directly bound by the adenosine agonist, whereas Tbet⁺ Th1 and Foxp3⁺ Treg differentiation appeared not to be regulated by A2aR signaling (Fig. 3C-E). A small, but statistically insignificant increase in ROR γ t⁺ Th17 cells was also observed in KO mice treated with CGS (Fig. 3C-E). Thus, direct CD4 T cell A2aR signaling shifts the balance of differentiation away from the GC-Tfh fate toward Th17 effector cell generation during the primary response to antigen.

T cell-intrinsic A2aR activation reduces T-dependent B cell immunity

GC-Tfh cells promote the survival, differentiation, isotype class switch, and affinity maturation of antigen-specific B cells in germinal centers (21). Therefore, we hypothesized that A2aR signaling in T cells during primary immunization would interfere with the T-dependent B cell response to vaccination. To test this, WT and CD4-Cre *Adora2a*^{fl/fl} mice (KO) mice were immunized with a protein complex containing 2W1S coupled to PE (2W1S-PE) either with or without CGS treatment, and then PE-specific B cells were enriched using magnetic beads and characterized by flow cytometry. An ~50-fold expansion of PE-specific

B cells was seen in WT and KO PBS-treated mice following immunization, as compared to naïve mice (Fig. 4A-C). Consistent with the hypothesis, the number of PE-specific B cells found after vaccination was significantly reduced in CGS-treated WT hosts, but not in mice whose CD4 T cells lacked A2aRs. CGS treatment appeared to have its greatest inhibitory effect on the frequency and number of GC-phenotype CD38⁻ GL7⁺ PE-binding B cells in the WT mice, although all B cell subpopulations were affected (Fig. 4A-D). Importantly, these inhibitory effects of CGS on PE-specific B cells during immunization were blunted in mice that lacked *Adora2a* gene expression specifically within the T cell compartment. Therefore, these data suggest that the loss of antigen-specific GC-Tfh differentiation that occurs during strong A2aR signaling on CD4 T cells is sufficient to abrogate the provision of cognate T cell help to GC B cells during their primary response to antigen.

Discussion

The identification of novel signaling elements that fine-tune CD4 T cell lineage differentiation during primary immunization offers new opportunities to improve the efficacy of vaccines and targeted immunotherapies (22, 23, 24). Our data suggest that *in vivo* A2aR signaling during the primary response to antigen plus a strong adjuvant diverts CD4 T helper cells away from the Tfh and GC-Tfh lineages. Given the key role of alternative T differentiation fates such as Th17 in protection against mucosal barrier infections (22), it is conceivable that selective A2aR agonists could be useful during vaccination to shape an optimal T differentiation response against pathogens.

A2aRs also appear to be a particularly attractive therapeutic target for the treatment of B cell-dependent autoimmune disorders such as systemic lupus erythematosus (25) and rheumatoid arthritis (RA) (26). Indeed, previous studies have shown a positive correlation between the number of Tfh cells and disease burden in patients with RA (26). Perhaps consistent with this, A2aR agonists effectively suppress animal models of inflammatory arthritis (27). The fact that the first-line anti-rheumatic drugs methotrexate and sulfasalazine act, in part, through the generation of extracellular adenosine and A2aR signaling (28, 29), lends further support to the notion that A2aR signaling can ameliorate T-dependent B cell autoreactivity.

It should be noted that the ablation of A2aRs in these vaccination experiments using conditional knock-out mice failed to significantly enhance antigen-specific Tfh or GC-Tfh differentiation. Similarly, use of a selective antagonist of A2aRs during immunization did not reliably alter CD4 T cell differentiation (data not shown). Although strong A2aR signaling with an agonist can be inhibitory for Tfh and GC-Tfh differentiation in normal CD4 T cells, under normal circumstances endogenous extracellular adenosine may play no role in CD4 T cell fate selection within secondary lymphoid organs following *i.p.* immunization in adjuvant. Alternatively, unspecified factors (e.g., increased A2bRs, decreased adenosine kinase) may compensate for the loss of A2aRs in KO mice. Activated T cells are known to upregulate adenosine deaminase (ADA), an enzyme capable of metabolizing adenosine to inosine (30). Therefore, strong continuous A2aR signaling from endogenous adenosine sources may only occur under special circumstances such as hypoxia where CD73 is up-regulated to facilitate increased extracellular adenosine production in

close proximity to A2a receptors (31-33). Going forward, it will be important to identify the immunological context (spatial and temporal) whereby extracellular adenosine counter-regulates Tfh and GC-Tfh differentiation.

Acknowledgments

We thank Dr. Joel Linden from the La Jolla Institute for Allergy and Immunology for the *Adora2a^{fl/fl}* mice as well as Dr. Michael Farrar from the University of Minnesota for the CD4-Cre mice. We would also like to thank members of the Mueller and Jenkin's lab.

This work was supported by National Institutes of Health Grants: P01AI035296 (to D.L.M. and M.K.J.), and NIH Institutional Pre-Doctoral Training Grant: T32AI007313 (to S.S.), and by a research grant from the Lupus Foundation of Minnesota (to D.L.M.).

References

1. Streitová D, Sefc L, Savvulidi F, Pospíšil M, Holá J, Hofer M. Adenosine A(1), A(2a), A(2b), and A(3) receptors in hematopoiesis. 1. Expression of receptor mRNA in four mouse hematopoietic precursor cells. *Physiol Res*. 2010; 59:133–137. [PubMed: 19249907]
2. Koshiba M, Rosin DL, Hayashi N, Linden J, Sitkovsky MV. Patterns of A2A extracellular adenosine receptor expression in different functional subsets of human peripheral T cells. Flow cytometry studies with anti-A2A receptor monoclonal antibodies. *Mol Pharmacol*. 1999; 55:614–624. [PubMed: 10051547]
3. Cekic C, Sag D, Day Y, Linden J. Extracellular adenosine regulates naive T cell development and peripheral maintenance. *J Exp Med*. 2013; 210:2693–706. [PubMed: 24145516]
4. Zarek PE, Huang CT, Lutz ER, Kowalski J, Horton MR, Linden J, Drake CG, Powell JD. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. *Blood*. 2008; 11:251–259.
5. Naganuma M, Wiznerowicz EB, Lappas CM, Linden J, Worthington MT, Ernst PB. Cutting edge: Critical role for A2A adenosine receptors in the T cell-mediated regulation of colitis. *J Immunol*. 2006; 177:2765–2769. [PubMed: 16920910]
6. Sevigny CP, Li L, Awad AS, Huang L, McDuffie M, Linden J, Lobo PI, Okusa MD. Activation of adenosine 2A receptors attenuates allograft rejection and alloantigen recognition. *J Immunol*. 2007; 178:4240–4249. [PubMed: 17371980]
7. Cekic C, Linden J. Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment. *Cancer Res*. 2014; 74:7239–7249. [PubMed: 25341542]
8. Lappas CM, Rieger JM, Linden J. A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. *J Immunol*. 2005; 174:1073–1080. [PubMed: 15634932]
9. Liang D, Zuo A, Shao H, Chen M, Kaplan HJ, Sun D. Anti-inflammatory or proinflammatory effect of an adenosine receptor agonist on the Th17 autoimmune response is inflammatory environment-dependent. *J Immunol*. 2014; 193:5498–5505. [PubMed: 25367119]
10. Wang L, Wan H, Tang W, Ni Y, Hou X, Pan L, Song Y, Shi G. Critical roles of adenosine A2A receptor in regulating the balance of Treg/Th17 cells in allergic asthma. *Clin Respir J*. 2016; doi: 10.1111/crj.12503
11. Francois V, Shehade H, Acolty V, Preyat N, Delrée P, Moser M, Oldenhove G. Intestinal immunopathology is associated with decreased CD73-generated adenosine during lethal infection. *Mucosal Immunol*. 2015; 8:773–784. [PubMed: 25389034]
12. Proietti M, Cornacchione V, Rezzonico Jost T, Romagnani A, Faliti CE, Perruzza L, Rigoni R, Radaelli E, Caprioli F, Preziuso S, Brannetti B, Thelen M, Mc Coy KD, Slack E, Traggiai E, Grassi F. ATP-gated ionotropic P2X7 receptor controls follicular T helper cell numbers in peyer's patches to promote host-microbiota mutualism. *Immunity*. 2014; 41:789–801. [PubMed: 25464855]
13. Crotty S. T follicular helper cell differentiation, function, and roles in disease. *Immunity*. 2014; 41:529–542. [PubMed: 25367570]

14. Yang JA, Tubo NJ, Gearhart MD, Bardwell VJ, Jenkins MK. Cutting Edge: Bcl6-interacting corepressor contributes to germinal center T follicular helper cell formation and B cell helper function. *J Immunol.* 2015; 194:5604–5608. [PubMed: 25964495]
15. Kalekar LA, Schmiel SE, Nandiwada SL, Lam WY, Barsness LO, Zhang N, Stritesky GL, Malhotra D, Pauken KE, Linehan JL, O'Sullivan MG, Fife BT, Hogquist KA, Jenkins MK, Mueller DL. CD4(+) T cell anergy prevents autoimmunity and generates regulatory T cell precursors. *Nature Immunol.* 2016; 17:304–314. [PubMed: 26829766]
16. Martinez R, Zhang N, Thomas S, Nandiwada SL, Jenkins MK, Binstadt BA, Mueller DL. Arthritogenic self-reactive CD4+ T cells acquire an FR4hi CD73hi anergic state in the presence of Foxp3+ regulatory T cells. *J Immunol.* 2012; 188:170–181. [PubMed: 22124124]
17. Erdmann AA, Gao Z, Jung U, Foley J, Borenstein T, Jacobson KA, Fowler DH. Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. *Blood.* 2005; 105:4707–4714. [PubMed: 15746085]
18. Iyer SS, Latner DR, Zilliox MJ, McCausland M, Akondy RS, Penaloza-Macmaster P, Hale JS, Ye L, Mohammed AU, Yamaguchi T, Sakaguchi S, Amara RR, Ahmed R. Identification of novel markers for mouse CD4(+) T follicular helper cells. *Eur J Immunol.* 2013; 43:3219–3232. [PubMed: 24030473]
19. Hatzi K, Nance JP, Kroenke MA, Bothwell M, Haddad EK, Melnick A, Crotty S. BCL6 orchestrates Tfh cell differentiation via multiple distinct mechanisms. *J Exp Med.* 2015; 212:539–553. [PubMed: 25824819]
20. Liu X, Nurieva R, Dong C. Transcriptional regulation of follicular T-helper (tfh) cells. *Immunol Rev.* 2013; 252:139–145. [PubMed: 23405901]
21. Kitano M, Moriyama S, Ando Y, Hikida M, Mori Y, Kurosaki T, Okada T. Bcl6 protein expression shapes pre-germinal center B cell dynamics and follicular helper T cell heterogeneity. *Immunity.* 2011; 34:961–972. [PubMed: 21636294]
22. Tubo N, Pagán A, Taylor J, Nelson RW, Linehan JL, Ertelt JM, Huseby ES, Way SS, Jenkins MK. Single naive CD4+ T cells from a diverse repertoire produce different effector cell types during infection. *Cell.* 2013; 153:785–796. [PubMed: 23663778]
23. Malhotra D, Linehan JL, Dileepan T, Lee YJ, Purtha WE, Lu JV, Nelson RW, Fife BT, Orr HT, Anderson MS, Hogquist KA, Jenkins MK. Tolerance is established in polyclonal CD4(+) T cells by distinct mechanisms, according to self-peptide expression patterns. *Nature Immunol.* 2016; 17:187–195. [PubMed: 26726812]
24. Gong C, Linderman JJ, Kirschner D. Harnessing the Heterogeneity of T Cell Differentiation Fate to Fine-Tune Generation of Effector and Memory T Cells. *Front Immunol.* 2014; 5:57. [PubMed: 24600448]
25. Terrier B, Costedoat-Chalumeau N, Garrido M, Geri G, Rosenzweig M, Musset L, Klatzmann D, Saadoun D, Cacoub P. Interleukin 21 correlates with T cell and B cell subset alterations in systemic lupus erythematosus. *J Rheum.* 2012; 39:1819–1828. [PubMed: 22859347]
26. Wang J, Shan Y, Jiang Z, Feng J, Li C, Ma L, Jiang Y. High frequencies of activated B cells and T follicular helper cells are correlated with disease activity in patients with new-onset rheumatoid arthritis. *Clin Exp Immunol.* 2013; 174:212–20. [PubMed: 23786438]
27. Vincenzi F, Padovan M, Targa M, Corciulo C, Giacuzzo S, Merighi S, Gessi S, Govoni M, Borea PA, Varani K. A(2A) adenosine receptors are differentially modulated by pharmacological treatments in rheumatoid arthritis patients and their stimulation ameliorates adjuvant-induced arthritis in rats. *PLoS One.* 2013; 8:e54195. [PubMed: 23326596]
28. Morabito L, Montesinos MC, Schreiber DM, Balter L, Thompson LF, Resta R, Carlin G, Huie MA, Cronstein BN. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides. *J Clin Invest.* 1998; 101:295–300. [PubMed: 9435300]
29. Riksen NP, Barrera P, van den Broek PHH, van Riel PLCM, Smits P, Rongen GA. Methotrexate modulates the kinetics of adenosine in humans in vivo. *Ann Rheum Dis.* 2006; 65:465–470. [PubMed: 16308339]

30. Martín M, Huguet J, Centelles JJ, Franco R. Expression of ecto-adenosine deaminase and CD26 in human T cells triggered by the TCR-CD3 complex possible role of adenosine deaminase as costimulatory molecule. *J Immunol.* 1995; 155:4630–4643. [PubMed: 7594462]
31. Choukèr A, Thiel M, Lukashev D, Ward JM, Kaufmann I, Apasov S, Sitkovsky MV, Ohta A. Critical role of hypoxia and A2A adenosine receptors in liver tissue-protecting physiological anti-inflammatory pathway. *Mol Med.* 2008; 14:116–123. [PubMed: 18163162]
32. Hatfield SM, Sitkovsky MV. A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1 α driven immunosuppression and improve immunotherapies of cancer. *Curr Opin Pharmacol.* 2016; 29:90–6. [PubMed: 27429212]

Abbreviations

B6	C57BL/6
A2aR	adenosine 2a receptors
FR4	folate receptor 4
GC	germinal center
CGS	CGS-21680
LN	lymph node
Tfh	T follicular helper
Treg	regulatory T cell




Figure 1. A2aR signaling using the selective agonist CGS-21680 does not promote energy or Treg induction during primary immunization

B6 mice were immunized with 2W1S-PE and subsequently given a 7d treatment course of the selective A2aR agonist *CGS* 2.5 mg/kg or vehicle alone (*PBS*). (A) The frequency and number of spleen and LN 2W1S:I-A^b-specific CD4 T cells (with naïve untreated mice shown for reference). (B) Foxp3⁺ Tregs within the 2W1S:I-A^b-specific CD4 T cell compartment. (C) CD73⁺ FR4⁺ anergic-phenotype cells within the conventional Foxp3⁻ 2W1S:I-A^b-specific CD4 T cell population. (D) Ki67 expression in conventional Foxp3⁻ 2W1S:I-A^b-specific CD4 T cells 7d after 2W1S-PE immunization in the presence of CGS (*2W1S peptide/CGS*) or vehicle alone (*2W1S peptide/PBS*) (with endogenous naive polyclonal CD44^{lo} CD4 T cells shown as a control). Data are representative from three independent experiments (n=8-9 mice per group). *P < 0.05, **P < 0.01, and ***P < 0.001




Figure 2. A2aR activation reduces Tfh and GC-Tfh differentiation

2W1S:I-A^b tetramer-binding T cells were recovered from the spleen and LNs of 2W1S-PE immunized WT B6 mice after 7d of treatment with either *CGS* or vehicle alone (*PBS*). (A) FR4 and CXCR5, (B) CD73 and CXCR5, (C) PD-1 and CXCR5, and (D) Bcl6 and CXCR5 staining in 2W1S:I-A^b-specific CD4 T cells from *CGS*- or *PBS*-treated immunized mice. (E) Aggregate numbers of Bcl6^{hi} CXCR5^{hi} GC-Tfh, Bcl6^{lo} CXCR5^{lo} Tfh, and Bcl6⁻ CXCR5⁻ non-Tfh cells that bind the 2W1S:I-A^b tetramer. Data are representative of three independent experiments (n=8-9 mice). *P < 0.05, **P < 0.01, and ***P < 0.001




Figure 3. A2aR inhibition of GC-Tfh differentiation is T cell intrinsic

2W1S:I-A^b tetramer-bound CD4 T cells were enriched from spleen and LNs of CD4-Cre *Adora2a*^{f/f} conditional knock-out (KO) mice as well as non-Cre expressing WT littermates after 2W1S-PE immunization and a 7d course of either CGS or PBS treatment. (A, B) Frequency (A) and number (B) of 2W1S-specific CD44^{hi} Foxp3⁻ CD4 T cell subsets: Bcl6^{hi} CXCR5^{hi} GC-Tfh, Bcl6^{lo} CXCR5^{lo} Tfh, and Bcl6⁻ CXCR5⁻ non-Tfh cells. (C, D) Frequency (C) and number (D) of Th17 (RORγt⁺ Tbet⁻) and Th1 (RORγt⁻ Tbet⁺) lineage cells within the non-Tfh fraction of 2W1S:I-A^b tetramer-binding CD4 T cells. (E) 2W1S-specific Foxp3⁺ Treg numbers. Data are representative of three independent experiments (n=8-9). *P < 0.05, **P < 0.01, and ***P < 0.001




Figure 4. T cell A2aR activation reduces GC B cell immunity

PE-specific B cells were enriched from the spleen and LNs of 2W1S-PE primed *WT* or *CD4-Cre Adora2a^{fl/fl}* conditional knock-out (*KO*) mice given a 7d course of *CGS* or the *PBS* vehicle alone. (A) Gating strategy to identify PE-specific B220⁺ total B cells (*left column*), B220^{intermediate} intracellular Ig (H+L)^{hi} plasma cells (*middle column*), as well as intracellular Ig (H+L)^{intermediate} CD38⁻ GL7⁺ GC B cells (*right column*) in control untreated (*upper row*), 2W1S-PE immunized and PBS-treated (*middle row*), and 2W1S-PE immunized and CGS-treated (*lower row*) *WT* mice. (B) Representative *KO* mice treated as in (A). (C) Absolute numbers of total PE-specific B cells in *WT* and *KO* mice treated as in (A) and (B), with untreated mice shown as a control. (D) Absolute numbers and frequency of PE-specific polyclonal CD38⁻ GL7⁺ GC B cells in immunized *WT* and *KO* mice treated as in (A) and (B). Data are representative of three independent experiments (n=8-9 mice). *P < 0.05, **P < 0.01, and ***P < 0.001